

PSEUDOMONAS-CF-IgG ELISA KIT



STATENS
SERUM
INSTITUT

*prevents and controls
infectious diseases,
biological threats, and
congenital disorders*

FOR IN VITRO DIAGNOSTIC USE

- *Surveillance of CF patients*
- *Detects chronic infection*
- *Guides antibiotic therapy*

Statens Serum Institut
SSI Diagnostica
2 Herredsvejen
3400 Hillerød
Denmark

Tel.: +45 4829 9178
Fax: +45 4829 9179
microbiology@ssi.dk
www.ssi.dk

Description

The Pseudomonas-CF-IgG ELISA kit is for the quantitative measurement of the antibody level of *Pseudomonas aeruginosa* in human serum samples.

The Pseudomonas-CF-IgG kit is supplied with one ELISA plate and all required reagents to perform 96 tests (including standards). It is recommended to perform at least 4 patient samples at the same time. The antigen is obtained by sonication of the 17 most common *P. aeruginosa* serotypes. More than 64 different antigens are detectable in the antigen pool. The standard control serum contains high titer antibodies directed against *P. aeruginosa*.

Background

P. aeruginosa is the most important bacterial pathogen in patients with cystic fibrosis. Chronic pulmonary infection with *P. aeruginosa* is responsible for most of the morbidity and mortality in cystic fibrosis.

Chronic *P. aeruginosa* infection can reliably be discriminated from intermittent colonization by measuring serum IgG antibodies against *P. aeruginosa*. During the chronic infection a pronounced and increasing antibody response develops whereas this is not the case in intermittently colonized patients. The level of the antibody response in chronically infected patients correlates to the severity of the infection.

Since cystic fibrosis patients may experience repeated intermittent *P. aeruginosa* colonization, they will be subject to repeated courses of antibiotic therapy. Measurements of the antibody response in such cases can be helpful in the management of the infection.

Principle

The PSEUDOMONAS-CF-IgG ELISA Kit is a traditional ELISA setup. The results from the pooled human standard serum are used to calculate the concentration of antiserum in the patient sample. The test can be performed during a working day (approximately 4½ hours) or divided over two working days.

Support

Sera producing unexplainable results may be sent to the Reference Laboratory at the Department of Clinical Microbiology & Danish Cystic Fibrosis Centre, Rigshospitalet, University of Copenhagen, Denmark together with information about the bacteriological status of the patient for absorption of possible cross-reactive antibodies. E-mail: hoiby@hoibyniels.dk for further information.

Storage and Shelf Life

Store the Rabbit-Anti-Human IgG HRP and TMB Plus Substrate at 2-8°C. All other reagents can be stored at room temperature. Expiry date of the kit is printed on the package.

Available Products

- Pseudomonas-CF-IgG kit (Art. No. 64742)
- Pseudomonas-CF-IgG antigen (Art. No. 60899) and Pseudomonas-CF-IgG standard control serum (Art. No. 60900) are still available for separate purchasing.

Information and Ordering

Statens Serum Institut
Diagnostics Sales and Marketing
2 Herredsvejen
3400 Hillerød
Denmark
Tel.: +45 4829 9178
Fax.: +45 4829 9179
microbiology@ssi.dk
www.ssi.dk

References

- Tacjana Pressler et al: Diagnostic significance of measurements of specific IgG antibodies to *Pseudomonas aeruginosa* by three different serological methods. J Cystic Fibrosis 8; 37-42; 2009.
- Tacjana Pressler et al: Early rise of anti- *Pseudomonas* antibodies and a mucoid phenotype of *Pseudomonas aeruginosa* are risk factors for development of chronic lung infection - A case control study. J Cystic Fibrosis 5; 9-15; 2006.
- Høiby N et al: Eradication of early *Pseudomonas aeruginosa* infection. J Cystic Fibrosis 4:49-54; 2005.
- Döring G & Høiby N for the consensus study group: Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cystic Fibrosis 3:67-91; 2004.
- Johansen H K et al: Antibody response to *Pseudomonas aeruginosa* in cystic fibrosis patients - a marker of therapeutic success? -A 30-year cohort study of survival in Danish CF patients after onset of chronic *P. aeruginosa* lung infection. Pediatr Pulmonol 37:427-432; 2004.
- Frederiksen B et al: Changing epidemiology of *Pseudomonas aeruginosa* infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 28:159-66; 1999.

